ICMR approves RT-PCR Omicron detection kit

Since the test can differentiate between variants, it’s also ideal for entry point screening of travelers at airports

220
ICMR

Last Updated on January 21, 2022 by The Health Master

The Indian Council of Medical Research (ICMR) has approved the KRIVIDA Novus RT-PCR kit, developed by Chennai-based KRIYA Medical Technologies in collaboration with ImmuGenix Bioscience.

The kit can reportedly detect the SARS-CoV-2 virus and also differentiate the Omicron variant from Delta and other variants. The test takes just about 45 minutes to detect the infection and determine the variant.

Commenting on the approval, Anu Moturi, CEO and Founder, KRIYA Medical Technologies said, “KRIVIDA Novus is a one of its kind test that not only differentiates the variants, but also  detects the sub-lineages of Omicron.

The kit is compatible with Real-Time PCR machines with a test  run time of roughly 45 minutes. It not only tackles the issue of delayed testing, but it also helps in swift prevention of spread.

Furthermore, since the test can differentiate between variants, it’s also ideal for entry point screening of travelers at airports. ”

Dr Naveen Kumar Venkatesan, Chief Scientist, Founder and Director, ImmuGenix Biosciences said, “Currently, patients who test positive for C-19 have to undergo genome sequencing to know the variant they have been infected with.

KRIVIDA Novus kit employs a specific pattern of a unique combination of ‘SGTF’ (S Gene Target Failure) strategy and ‘Omicron specific amplification signal’ to detect the variant. The kit detects the Omicron variant (B.1.1.529) and all its sub-lineages, such as BA.1, BA.2 and BA.3”

In a single-tube assay, the KRIVIDA Novus kit can detect C-19 and differentiate the other variants from Omicron.

 Thekit is compatible with most Real-Time PCR machines with a test run time of 45 minutes, enabling the testing sites to conduct 2,160 tests within 24 hrs.

The kit detects SARS-CoV-2 using  five different gene targets and it has a  variant specific S gene probe for the newly emerged Omicron and reportedly picks up all the sub-lineages of Omicron, such as, BA.1, BA.2 and  BA.3. The test is most suitable for entry point screening at airports, as er a release.

KRIVIDA Novus will be produced at KRIYA’s state-of-the-art manufacturing facility in Oragadam in Chennai.

The company currently has a manufacturing capacity of 5 million kits and plans to increase it to 10 million within a week depending on the demand.

The test is priced competitively, and it will soon be commercially available across the country.

DCGI needs more safety data for Covaxin nod for under 12

USFDA approves add-on therapy to lower Cholesterol

Capsule introduced that can inhibit viral replication

Drug alert: 33 out of 1385 samples declared as NSQ in December 2021

Govt issues revised guidelines on use of drugs in Covid patients

USFDA gives approval to Strides Pharma for generic Tamiflu

DCGI gives nod to for Phase 3 Clinical Trial on drug…

Pharmaceutical Budget 2022: Expectations

NPPA to conduct study on Price Regulatory Policies in these 10…

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner